Phased variability in cell fate determination orchestrates antibody evolution
Cell Systems · 2026-06 · 17 (6) · 101649
DOI: 10.1016/j.cels.2026.101649 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Systems, 2026-06. Verfasst von Zhaolin Hua. Beteiligte Einrichtung: State Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; University of C…. Hauptthemen laut MEDLINE: B-Lymphocytes, Antibody Affinity, Antibodies. Die Arbeit nennt 9 Literaturangaben. Gefördert von: National Science and Technology Major Project, National Major Science and Technology Projects of China.
Abstract (Originalsprache)
Antibody affinity maturation relies on somatic hypermutation and affinity-based selection of B cell clones. A new study shows that phased variability in B cell fate decisions, often encoded by non-genetic cellular states, enhances this evolutionary process by permitting the emergence and persistence of rare outlier cells with advantageous properties.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China; University of Chinese Academy of Sciences, Beijing, China. Electronic address: zlhua@…
Förderung
- National Science and Technology Major Project
- National Major Science and Technology Projects of China
Zitieren
APA
Hua, Z. (2026). Phased variability in cell fate determination orchestrates antibody evolution. Cell Systems, 17(6), 101649. https://doi.org/10.1016/j.cels.2026.101649
Vancouver
Hua Z. Phased variability in cell fate determination orchestrates antibody evolution. Cell Systems. 2026;17(6):101649. doi:10.1016/j.cels.2026.101649
BibTeX
@article{Hua2026,
author = {Hua, Zhaolin},
title = {Phased variability in cell fate determination orchestrates antibody evolution},
journal = {Cell Systems},
year = {2026},
volume = {17},
number = {6},
pages = {101649},
doi = {10.1016/j.cels.2026.101649}
}
EUVIMED